Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Trinity Biotech (TRIB) Notes Payables (2021 - 2022)

Historic Notes Payables for Trinity Biotech (TRIB) over the last 2 years, with Q3 2022 value amounting to $210000.0.

Trinity Biotech's Notes Payables changed N/A to $210000.0 in Q3 2022 from the same period last year, while for Sep 2022 it was $210000.0, marking a year-over-year change of. This contributed to the annual value of $83.3 million for FY2021, which is N/A changed from last year.
Trinity Biotech's Notes Payables amounted to $210000.0 in Q3 2022.
Trinity Biotech's Notes Payables' 5-year high stood at $83.3 million during Q4 2021, with a 5-year trough of $210000.0 in Q1 2022.